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Introduction {#sec005}
============

Mycobacterium tuberculosis (*M*. *tuberculosis*) is the second most common infectious cause of death in adults worldwide (HIV is the most common). The human host serves as a natural reservoir for *M*. *tuberculosis*, which is an intracellular obligate and aerobic bacillus that multiplies within macrophages. The bacterium triggers the production of free radicals and avoids being killed by the same radicals \[[@pone.0154716.ref001]\]. In the lungs, macrophages produce cytokines and chemokines that attract other phagocytic cells, including monocytes, other alveolar macrophages, and neutrophils, which eventually form a nodular granulomatous structure called a tubercle. The ability of *M*. *tuberculosis* to efficiently establish latent infection has enabled it to spread to nearly one-third of individuals worldwide.

Sarcoidosis is a systemic granulomatous disease characterized by the formation of epithelioid cell granulomas (and is accompanied by an infiltration of inflammatory cells) without caseous necrosis. Multisystem granulomatous inflammation involving the lungs, lymph nodes, skin, eyes, heart, and muscles is a hallmark of sarcoidosis. Infectious and genetic factors, as well as autoimmunity, are considered to be potential causes of SA \[[@pone.0154716.ref002]--[@pone.0154716.ref004]\]. In addition, mycobacterial antigens, such as the 6-kDa ESAT6, catalase---peroxidase (mKatG), superoxide dismutase A (Sod A) and *M*. *tuberculosis* heat shock proteins (Mtb-hsp) have been suggested to be infectious factors for the pathogenesis of SA \[[@pone.0154716.ref005]\].

In the middle of the 20th century, *M*. *tuberculosis* was isolated from several sarcoidosis patients by Scadding \[[@pone.0154716.ref006]\]. The relationship between *M*. *tuberculosis* and sarcoidosis has since been explored with increasing frequency. The advent of molecular biology invigorated the search for mycobacterial DNA in sarcoidosis patients \[[@pone.0154716.ref007], [@pone.0154716.ref008]\]. One meta-analysis conducted by Gupta \[[@pone.0154716.ref009]\] compiled 31 published studies on the presence of mycobacteria in sarcoidosis patients. The authors concluded that the evidence from pooled analysis favored the existence of an association between mycobacteria and sarcoidosis.

Recent studies evaluating immunological evidence of mycobacterial antigens in sarcoidosis patients has renewed interest in the role of mycobacteria in sarcoidosis \[[@pone.0154716.ref010]\], indicating that *M*. *tuberculosis* antigens could be involved in the pathogenesis of sarcoidosis. Many studies on the T-cell response to *M*. *tuberculosis* antigens have been conducted using an interferon gamma release assay (IGRA), which has been proven to be more efficient than the TST (tuberculin skin test) \[[@pone.0154716.ref011]\]. We conducted a meta-analysis of the available published literature to analyze the role of mycobacteria in the pathogenesis of sarcoidosis.

Materials and Methods {#sec006}
=====================

Search strategy and selection criteria {#sec007}
--------------------------------------

The aim of this meta-analysis was to collect all publicly available studies on the immune response to *M*. *tuberculosis* antigens in patients with sarcoidosis. To identify relevant articles for inclusion in this review, all authors independently searched PubMed, Embase, and Cochrane Library databases for relevant studies published from 1990--2015 using the following terms: sarcoidosis AND mycobacteria (OR) mycobacterium; sarcoidosis AND mycobacterium tuberculosis; and sarcoidosis AND tuberculosis. Additional eligible studies were identified by reviewing the references of all retrieved- literatures and review articles addressing the relationship between sarcoidosis and mycobacteria. The outcome measure of all included studies was positivity incidence of the immune response to *M*. *tuberculosis* antigens. No language or geographic restrictions were imposed on identified studies.

Data abstraction and Quality Assessment {#sec008}
---------------------------------------

Paired reviewers (Chuling Fang and Hui Huang) independently evaluated studies for eligibility using a two-stage procedure. During the first stage, all identified abstracts were evaluated to ensure that they were involved in the relationship between sarcoidosis and mycobacteria. All potentially relevant studies were retrieved and selected for the second stage of the procedure, in which a full-text review was performed to determine whether the studies provided the positivity incidence of the immune response. Any disagreements were resolved by discussion and consensus. Data concerning the immune response to *M*. *tuberculosis* antigens were extracted onto standardized data collection forms by the two reviewers, and the verified data were entered into a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA). The following items were extracted: 1) the publication details including the study geography (country or region), year of publication, first author and other citation details; 2) the number of patients with sarcoidosis and the type of mycobacterium (*M*. *tuberculosis* or other mycobacterium) used in analysis; 3) details of the technique used to evaluate the immune response in samples; 4) the health condition of the control subjects and whether details on TST outcomes were provided and 5) the numbers of the samples with an active immune response to mycobacterial antigens for patients with sarcoidosis and control. No attempt was made to include unpublished data. Methodological quality was assessed by the Newcastle-Ottawa Scale (NOS).

Data Synthesis and Analysis {#sec009}
---------------------------

The included articles were analyzed using Cochrane Collaboration Review Manager statistical software (version 5.3; Cochrane Collaboration, Oxford, UK). To calculate the percentage of sarcoidosis samples with a positive immune reaction to *M*. *tuberculosis*, binomial proportions were used in which the numerator was sarcoid samples with active immune response to *M*. *tuberculosis* antigens and the denominator was the total number of study samples. As dichotomous outcomes, the percentage of sarcoid samples with a positive immune response out of the total samples versus the same percentage of control samples was expressed as an odds ratio (OR) and a 95% confidence interval (CI). The fixed-effects model was used, and the random-effects model weighted by the Mantel-Haenszel method was utilized for data with significant heterogeneity (P value of x^2^ test \<0.05 and *I*^2^ \>50%). P\<0.05 was considered statistically significant.

Assessment of heterogeneity {#sec010}
---------------------------

The impact of heterogeneity on the pooled estimates of individual outcomes of meta-analysis was assessed using the Chi-squared test and/or I^2^ test (this test measures the extent of inconsistency among studies' results and is interpreted as the approximate proportion of total variation in study estimates due to heterogeneity rather than sampling error). An I^2^ value \>50% indicates significant heterogeneity.

Assessment of publication bias {#sec011}
------------------------------

A funnel plot test was used to assess publication bias. The funnel plot is a measurement of the log of the OR (on the X-axis; a measurement of diagnostic accuracy) against the standard error of the log of the OR (on the Y-axis; an indicator of sample size). Each point represents a study in meta-analysis.

Results {#sec012}
=======

Study Identification {#sec013}
--------------------

The process of identifying eligible studies is summarized in [Fig 1](#pone.0154716.g001){ref-type="fig"}. Studies were retrieved using the aforementioned process. After an evaluation of the title and abstract, 71 studies were subjected to further assessments. After full-text reviews, 13 trials (13articles) were included in meta-analysis, and related data were extracted. Detailed characteristics of the included studies are provided in [Table 1](#pone.0154716.t001){ref-type="table"}. The 13 studies \[[@pone.0154716.ref012]--[@pone.0154716.ref024]\] published between 1996 and 2014 enrolled a total of 733 participants: 555 involving the T-cell response (253 in the sarcoidosis group, 302 in the control group with PPD-, unknown PPD status or PPD+ (LTBI)); and 178 Involving the humoral response (100 in the sarcoidosis group and 78 in the control group). Six of the trials were conducted in the USA \[[@pone.0154716.ref013], [@pone.0154716.ref016]--[@pone.0154716.ref019], [@pone.0154716.ref022]\], two were performed in India \[[@pone.0154716.ref014], [@pone.0154716.ref020]\], and one each was carried out in Germany \[[@pone.0154716.ref015]\], the Netherlands \[[@pone.0154716.ref012]\], Poland \[[@pone.0154716.ref021]\], Sweden \[[@pone.0154716.ref023]\] and Australia \[[@pone.0154716.ref024]\] respectively.

![Flow diagram of assessment of studies identified in meta-analysis.](pone.0154716.g001){#pone.0154716.g001}

10.1371/journal.pone.0154716.t001

###### Studies evaluating the role of mycobacteria in sarcoidosis using immunology analysis.

![](pone.0154716.t001){#pone.0154716.t001g}

  First author                  Year   Site          Technique                                                                           Patients   Control                                                                                                                                                                 
  ----------------------------- ------ ------------- ----------------------------------------------------------------------------------- ---------- -------------------------------------------- ---- ------ ------ ------------------------------------------------------------------------------------------------------- -------
  **T-cell immune responses**                                                                                                                                                                                                                                                                                               
  Hofland                       2014   Netherlands   IFN-γ ELISpot measuring responses to PPD                                            5          BALF                                         32   MTB    13     Other causes of interstitial lung disease, unknown PPD                                                  86
  Ahmadzai                      2012   Australia     IFN-γ ELISpot measuring responses to ESAT-6 and KatG                                10         Peripheral blood mononuclear cells (PBMCs)   16   MTB    4/5    Healthy, PPD-/ PPD+(LTBI)                                                                               17/5
  Oswald-Richter                2012   USA           Flow cytometry measuring IFN-γ production in response to ESAT-6                     17         BALF                                         27   MTB    2      Disease control, PPD-                                                                                   14
  Gupta                         2011   India         QFT-GIT measuring responses to ESAT-6, CFP-10 and TB 7.7                            13         PBMCs                                        38   MTB    5      Healthy, PPD\<10mm                                                                                      18
  Horster                       2009   Germany       IFN-γ ELISPOT measuring responses to ESAT-6                                         7          BALF                                         15   MTB    7      Bacterial and viral pneumonia, cryptogenic organizing pneumonia, and bronchogenic carcinoma, PPD≤15mm   29
  Oswald-Richter                2009   USA           Flow cytometry measuring IFN-γproduction in responses to ESAT-6 and KatG            32         BALF                                         44   MTB    1      Disease control, PPD-                                                                                   27
  Drake                         2007   USA           Flow cytometry measuring IFN-γproduction in responses to ESAT-6 and KatG            15         PBMCs                                        26   MTB    1/7    Healthy, PPD-/ PPD+ (LTBI)                                                                              24/8
  Carlisle                      2007   USA           ELISPOT assessing Th1 responses to sodA, mkatG and ESAT-6                           12         PBMCs                                        30   MTB    1/6    Healthy, PPD-/ PPD+ (LTBI)                                                                              26/10
  Hajizadeh                     2007   USA           IFN-γ ELISPOT measuring responses to Antigen 85A                                    15         PBMCs                                        25   MTB    2/14   Healthy, PPD-/ PPD+ (LTBI)                                                                              22/16
  **humoral immunity**                                                                                                                                                                                                                                                                                                      
  Agarwal                       2012   India         Humoral responses to ESAT-6 and CFP-10                                              11         blood samples                                18   MTB    0      healthy, unknown PPD                                                                                    20
  Dubaniewicz                   2006   Poland        Anti-Mtb-hsp70, -Mtb-hsp65 and -Mtb-hsp16 antibodies                                12         blood samples                                37   MTB    0      PPD-                                                                                                    18
  Song                          2005   USA           IgG antibodies to mKatG                                                             12         PBMCs                                        25   MTB    0      healthy PPD−                                                                                            11
  El-Zaatari                    1996   Sweden        Humoral reactivities to *M*. *paratuberculosis* recombinant clones expressing p36   7          blood samples                                7    MPTB   13     Ulcerative colitis, noninflammatory bowel disease or healthy, unknown PPD                               38

BALF = Bronchoalveolar lavage fluid, PBMCs = Peripheral blood mononuclear cells, LTBI = Latent tuberculosis infection.

All studies performed detailed immunology analysis and the meta-analysis included studies conducted around the world ([Table 1](#pone.0154716.t001){ref-type="table"}). In total, the studies included 353 samples (235 blood samples and 118 BALF samples) from 353 patients with proven sarcoidosis as well as 380 samples (224 blood samples and 156 BALF samples) from 380 controls (with another lung disease or healthy with PPD-, PPD+ or unknown PPD status). Nine studies \[[@pone.0154716.ref012]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] on T-cell immune response were included. Among them, the control group in two studies \[[@pone.0154716.ref013], [@pone.0154716.ref016]\] were composed of PPD- individuals, those in other three studies \[12, 14, 15)\] contained individuals with an unknown PPD status, and the remaining four \[[@pone.0154716.ref017]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] used two control groups at the same time, consisted of PPD+ (LTBI) individuals and PPD- individuals respectively. Four studies \[[@pone.0154716.ref020]--[@pone.0154716.ref023]\] were included with humoral immune responses, the control groups of two studies \[[@pone.0154716.ref021], [@pone.0154716.ref022]\] among them were PPD-, and the other two studies \[[@pone.0154716.ref020], [@pone.0154716.ref023]\] were with unknown PPD subjects.

The quality scores of all 13 included studies were above five points, ranging from five to nine points. Five studies \[[@pone.0154716.ref012], [@pone.0154716.ref013], [@pone.0154716.ref016], [@pone.0154716.ref020], [@pone.0154716.ref024]\] achieved the highest score, and four others \[[@pone.0154716.ref014], [@pone.0154716.ref015], [@pone.0154716.ref018], [@pone.0154716.ref019]\] also achieved high score ([Table 2](#pone.0154716.t002){ref-type="table"}). All studies were case control studies. All of the cases had adequate definitions with independent validation. Four studies \[[@pone.0154716.ref012], [@pone.0154716.ref013], [@pone.0154716.ref016], [@pone.0154716.ref020]\] controlled age and sex to insure the comparability of cases and controls. In addition, four studies \[[@pone.0154716.ref020]--[@pone.0154716.ref023]\] utilized three different methods (ELISA, immunohistochemical analysis, or protein immunoblotting) to test the humoral response to *M*.*tuberculosis* antigens. Further, nine studies \[[@pone.0154716.ref012]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] used IGRA to test the T-cell response to these antigens.

10.1371/journal.pone.0154716.t002

###### The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies.

![](pone.0154716.t002){#pone.0154716.t002g}

  Non RCT studies                      Selection   Comparability   Exposure   Total Quality score                            
  ----------------------------- ------ ----------- --------------- ---------- --------------------- ---- ---- ---- ---- ---- ---
  **T-cell immune responses**                                                                                                
  **Hofland**                   2014   \*          \*              \*         \*                    \*   \*   \*   \*   \*   9
  **Ahmadzai**                  2012   \*          \*              \*         \*                    \*   \*   \*   \*   \*   9
  **Oswald-Richter**            2012   \*          \*              \*         \*                    \*   \*   \*   \*   \*   9
  **Gupta**                     2011   \*          \*              \*         \*                              \*   \*   \*   7
  **Horster**                   2009   \*          \*              \*         \*                              \*   \*   \*   7
  **Oswald-Richter**            2009   \*          \*              \*         \*                    \*   \*   \*   \*   \*   9
  **Drake**                     2007   \*          \*              \*         \*                              \*   \*   \*   7
  **Carlisle**                  2007   \*          \*              \*         \*                              \*   \*   \*   7
  **Hajizadeh**                 2007   \*                                     \*                              \*   \*   \*   5
  **Humoral immunity**                                                                                                       
  **Agarwal**                   2012   \*          \*              \*         \*                    \*   \*   \*   \*   \*   9
  **Dubaniewicz**               2006   \*                                     \*                              \*   \*   \*   5
  **Song**                      2005   \*                                     \*                              \*   \*   \*   5
  **El-Zaatari**                1996   \*                                     \*                              \*   \*   \*   5

one "\*" means one point.

T-cell immune response {#sec014}
----------------------

Nine trials \[[@pone.0154716.ref012]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] reported the positivity incidence of the T-cell immune response to *M*. *tuberculosis* specific antigens. Among the 253 samples in the sarcoidosis group, 126 exhibited a positive immune response to *M*. *tuberculosis* specific antigens, as demonstrated by immunology. The combined results of the nine trials revealed that the sarcoidosis patients had a significantly higher positivity rate of the T-cell immune response to *M*. *tuberculosis* specific antigens compared to the controls with PPD- or unknown PPD status (OR = 5.54, 95% CI: 3.56--8.61, P\<0.00001) ([Fig 2](#pone.0154716.g002){ref-type="fig"}). Combined analysis of six trials \[[@pone.0154716.ref013], [@pone.0154716.ref016]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] revealed that the sarcoidosis patients had a significantly higher positivity rate than the subgroup of PPD- controls (OR = 16.70, 95% CI: 8.19--34.08, P\<0.00001). Further, combined analysis of the three trials \[[@pone.0154716.ref012], [@pone.0154716.ref014], [@pone.0154716.ref015]\] revealed that the positivity rate of immune response in the sarcoidosis group did not significantly differ between the sarcoidosis patients and subgroup of controls with an unknown PPD status (OR = 1.48, 95% CI: 0.74--2.96, P = 0.26) ([Fig 2](#pone.0154716.g002){ref-type="fig"}). An additional combined analysis of four trials \[[@pone.0154716.ref017]--[@pone.0154716.ref019], [@pone.0154716.ref024]\] revealed that the sarcoidosis patients had significantly lower positivity rate than the PPD+ controls (LTBI) (OR = 0.26, 95% CI:0.10--0.66, P = 0.004) ([Fig 3](#pone.0154716.g003){ref-type="fig"}). Heterogeneity analysis revealed that there was no substantial heterogeneity in either the PPD- or unknown PPD control subgroups as assessed by using the I^2^ statistics (subgroup of PPD- controls (Q (d.f. = 5) = 4.57, P = 0.47, I^2^ = 0%); subgroup of controls with unknown PPD status (Q (d.f. = 2) = 1.24, P = 0.54, I^2^ = 0%)) ([Fig 2](#pone.0154716.g002){ref-type="fig"}). However, the heterogeneity between these two subgroups was substantial (Q (d.f. = 1) = 22.84, P\<0.00001, I^2^ = 95.6%) ([Fig 2](#pone.0154716.g002){ref-type="fig"}). Further, no substantial heterogeneity was detected in the PPD+ control group (Q (d.f. = 3) = 0.76 P = 0.86, I^2^ = 0%) ([Fig 3](#pone.0154716.g003){ref-type="fig"}). Publication bias was not evident, as estimated by generating a funnel plot for the studies on the T-cell immune response to *M*. *tuberculosis* specific antigens ([Fig 4a and 4b](#pone.0154716.g004){ref-type="fig"}).

![Forest plot of trials analyzing the positivity incidence of the T-cell response to *M*. *tuberculosis* antigens in sarcoidosis patients versus controls with PPD- and unknown PPD statuses.](pone.0154716.g002){#pone.0154716.g002}

![Forest plot of trials analyzing the positivity incidence of T-cell response to *M*. *tuberculosis* antigens in sarcoidosis patients versus PPD+ controls (LTBI).\
LTBI = latent tuberculosis infection.](pone.0154716.g003){#pone.0154716.g003}

![Funnel plot assessing publication bias.\
**a. Funnel plot for the studies on the T-cell response to *M*. *tuberculosis* antigens with controls of PPD- or unknown PPD status; b. Funnel plot for the studies on the T-cell response to *M*. *tuberculosis* antigens with PPD+ controls; c. Funnel plot for studies on the humoral response to *M*. *tuberculosis* antigens**. SA = sarcoidosis.](pone.0154716.g004){#pone.0154716.g004}

Humoral response {#sec015}
----------------

Four trials \[[@pone.0154716.ref020]--[@pone.0154716.ref023]\] reported the positivity incidence of the humoral immune response to *M*. *tuberculosis* specific antigens. Of the100 samples in the sarcoidosis group, 55 exhibited a positive immune response to *M*. *tuberculosis* specific antigens, as demonstrated by ELISA and immunohistochemical analysis. The combined results of four trials \[[@pone.0154716.ref020]--[@pone.0154716.ref023]\] revealed that the sarcoidosis group had a significantly higher positivity rate of humoral response to *M*. *tuberculosis* specific antigens than the control group (OR = 20.43, 95% CI: 5.53--75.53, P\<0.0001). Further, the combined results of two trials \[[@pone.0154716.ref021], [@pone.0154716.ref022]\] revealed that the sarcoidosis group had a significantly higher positivity rate of the humoral immune response to *M*. *tuberculosis* specific antigens than subgroup of PPD- controls (OR = 11.93, 95% CI: 2.15--66.27, P = 0.005). Similarly, combined analysis of another two trials \[[@pone.0154716.ref020], [@pone.0154716.ref023]\] revealed that the immune response positivity rate in the sarcoidosis group was significantly higher than that in the subgroup of controls with an unknown PPD status (OR = 41.97, 95% CI: 5.24--336.15, P = 0.0004) ([Fig 5](#pone.0154716.g005){ref-type="fig"}). Heterogeneity test revealed that there was not substantial heterogeneity in either of these two subgroups, as assessed using the I^2^ statistic (subgroup of PPD- controls (Q (d.f. = 1) = 0.28, P = 0.60, I^2^ = 0%); subgroup of controls with unknown PPD status (Q (d.f. = 1) = 0.14, P = 0.71, I^2^ = 0%)) ([Fig 5](#pone.0154716.g005){ref-type="fig"}). The heterogeneity between these two subgroups was also not substantial (Q (d.f. = 1) = 0.84, P = 0.36, I^2^ = 0%). Publication bias was not evident, as estimated by generation of a funnel plot for the studies on the T-cell immune response to *M*. *tuberculosis* specific antigens ([Fig 4c](#pone.0154716.g004){ref-type="fig"}).

![Forest plot of trials analyzing the positivity incidence of the humoral response to *M*. *tuberculosis* antigens in sarcoidosis patients versus controls.](pone.0154716.g005){#pone.0154716.g005}

Discussion {#sec016}
==========

Meta-analysis was the main method used in this research paper. It is more accurate and reliable than regression analysis or original papers.

The relationship between sarcoidosis and *M*. *tuberculosis* has been a highly contested and challenging issue. Further analysis is important considering their opposite therapeutic effects In the current meta-analysis, a greater positivity incidence of the immune response to *M*. *tuberculosis* specific antigens was observed in sarcoidosis group compared to the control group of subjects with PPD- or unknown PPD status for both the T-cell immune response and humoral response, indicating that these antigens induce T-cell-specific responses in the blood or BALF of sarcoidosis patients. However, it is important to note that sarcoidosis patients may be more likely to have positive TST results (i.e. to be more sensitive to LTBI) than healthy individuals due to unknown host factors with no known etiologic link between sarcoidosis and *M*. *tuberculosis*. Notably, the positivity incidence of T-cell immune response to *M*. *tuberculosis* specific antigens in sarcoidosis group was found to be significantly lower in the sarcoidosis patients than in the PPD+ (LTBI) controls, although the incidences did not differ among the four primary trials. Further, it was hypothesized that *M*. *tuberculosis* specific antigens response would not be observed in all sarcoidosis patients, and that the specific mycobacterial antigen may represent just one of the most important factors for the pathogenesis of sarcoidosis.

In the T-cell immune response, no significant heterogeneity was observed in either the subgroup of PPD- controls or in the subgroup of controls with an unknown PPD status. Similarly, no significant heterogeneity was detected in the group of PPD+ (LTBI) controls. Similarly, no significant heterogeneity was detected in the group of PPD+ (LTBI) controls. Further, in the humoral response, no significant heterogeneity was observed in either the subgroup of PPD- controls or the subgroup of controls with an unknown PPD status. However, significant heterogeneity was detected between the two subgroups with PPD- or unknown PPD status on the T-cell immune response, indicating that PPD status strongly influenced experimental outcome.

A number of original studies have examined mycobacteria in samples of sarcoidosis patients \[[@pone.0154716.ref007], [@pone.0154716.ref025]--[@pone.0154716.ref032]\], with different results. In addition, a meta-analysis \[[@pone.0154716.ref009]\] on the molecular evidence of the role of mycobacteria in sarcoidosis conducted in 2007 demonstrated mycobacterial presence in sarcoidosis lesions, suggesting the presence of an association between mycobacteria and sarcoidosis in some cases. However, it is important to emphasize that the mere presence of mycobacterial DNA does not indicate the existence of a cause-and-effect relationship. In 1998, evidence that the granulomatous response is driven by tissue antigens in sarcoidosis was provided by analysis of TCR expression \[[@pone.0154716.ref033]\]. Many recent studies have reported that *M*. *tuberculosis* antigens are involved in the pathogenesis of sarcoidosis \[[@pone.0154716.ref010], [@pone.0154716.ref034]\]. Among our included studies, one study conducted by Song reported the detection of several *M*. *tuberculosis* antigens including catalase‑peroxidase antigen (mKatG) and Mtb 16S rRNA in nearly 40% of their sarcoidosis subjects as detected by *in situ hybridization* \[[@pone.0154716.ref022]\]. Further, some studies have suggested that some antigens of *M*. *tuberculosis* (and not the whole mycobacteria) are involved in the pathogenesis of sarcoidosis \[[@pone.0154716.ref005], [@pone.0154716.ref016]\]. These data suggest the presence of mycobacterial proteins preferentially in sarcoidosis patients. Indeed, some factors do favor the involvement of mycobacteria in sarcoidosis, including the following: (1) histopathological appearances of the granulomas; (2) an immune response to *M*. *tuberculosis* antigens in sarcoidosis patients; (3) development of mycobacterial disease either coincidentally, before or after development of sarcoidosis \[[@pone.0154716.ref035]--[@pone.0154716.ref037]\]; (4) the detection of mycobacteria from samples of patients with sarcoidosis by PCR \[[@pone.0154716.ref026], [@pone.0154716.ref027]\]; and (5) acid-fast cell wall-deficient forms (CWDF) of bacteria can be grown from the blood of patients with sarcoidosis \[[@pone.0154716.ref038], [@pone.0154716.ref039]\]. It is important to note that mycobacterial (TB or NTM) antigens and not the active mycobacteria may play roles in the pathogenesis of sarcoidosis. One hypothesis is that an impediment in the removal of poorly degraded antigenic material may contribute to the pathogenesis of sarcoidosis \[[@pone.0154716.ref022], [@pone.0154716.ref040]\]. However, it is important to note that mycobacterial antigens alone cannot explain the pathogenesis of this disease in all subjects, as no immune response to *M*. *tuberculosis* antigens or molecular evidence was observed in some sarcoidosis subjects. Therefore, we assumed that other factors besides mycobacterial antigens contribute to the pathogenesis of sarcoidosis.

There are several limitations to this study. First, although data were collected from more than 700 patients, the number of incorporated studies was still small, and therefore these results may have been affected by publication bias. Second, the definite sensitivity of the immunological data is unknown, as they were not described or analyzed in detail in this study. Third, some variations may also have occurred due to differences in local environmental exposure and the fact that some sarcoidosis patients may have a disorder initiated by organisms or triggers other than mycobacteria. Therefore, additional studies would be useful to provide more concrete data to investigate the accuracy of this conclusion are needed.

In conclusion, the results of this meta-analysis have demonstrated an association between mycobacteria (especially *M*.*tuberculosis*) and sarcoidosis. Mycobacteria was not observed in all cases of sarcoidosis, however, these bacteria indeed represent an important factor involved in the pathogenesis of this disease. It has been hypothesized that only some specific, poorly degraded mycobacterial pathogenic antigens contribute to immune-mediated granulomatous inflammation rather than the whole active mycobacteria and that they elicit a type IV immune response.

Supporting Information {#sec017}
======================
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